NCT04631146 is a clinical trial of Camrelizumab in Non-small Cell Lung Cancer, sponsored by Guangdong Association of Clinical Trials.

Who is sponsoring NCT04631146?

NCT04631146 is sponsored by Guangdong Association of Clinical Trials.

What drugs are being tested in NCT04631146?

Interventions in NCT04631146: Camrelizumab.

What condition does NCT04631146 study?

NCT04631146 studies Non-small Cell Lung Cancer.

Is NCT04631146 still recruiting?

NCT04631146 is currently status unknown. Last updated 17 November 2020.

Last reviewed 2020-11-17 · How we verify

NCT04631146

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Camrelizumab in Real-World Study

Status unknown Last updated 17 November 2020

What this trial tests

trial testing Camrelizumab in Non-small Cell Lung Cancer in 450 participants. Status unknown.

Timeline

30 November 2020

Primary endpoint
30 June 2021

30 December 2021

Quick facts

Lead sponsor	Guangdong Association of Clinical Trials
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	450
Start date	30 November 2020
Primary completion	30 June 2021
Estimated completion	30 December 2021
Sites	1 location across China

Drugs / interventions tested

Camrelizumab — full drug profile →

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

Guangdong Association of Clinical Trials

Who can join

18 and older, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This observational real-world study is designed to evaluate the efficacy and safety of camrelizumab for the treatment of Chinese NSCLC patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004).
Liu SY, Chen Q, Zhou C, Zhang H, et al · · 2023 · cited 5× · PMID 36871274 · DOI 10.1007/s00262-023-03412-8
Efficacy and safety of camrelizumab-based comprehensive treatment for non-small cell lung cancer: a systematic review and meta-analysis.
Maimaitiyiming N, Li Y, Cao Y, Li Y. · · 2024 · cited 1× · PMID 39376584 · DOI 10.1177/17588359241284904

Verify or expand the search:

Other trials of Camrelizumab

Trials testing the same drug.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07466901 — A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Rad · NA · not yet recruiting
NCT07527026 — A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant T · Phase 2 · recruiting
NCT07266350 — A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for th · not yet recruiting

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other Guangdong Association of Clinical Trials trials

Trials by the same sponsor.

NCT07412262 — A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment · Phase 2 · not yet recruiting
NCT07416058 — PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC · Phase 2 · not yet recruiting
NCT07375316 — A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC · Phase 2 · recruiting
NCT07120698 — Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) · Phase 2 · recruiting
NCT07198620 — A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04631146 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Association of Clinical Trials
Last refreshed: 17 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04631146.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing